Circulating KIM-1 & ctDNA as Prognostic Markers in Oligometastatic Clear Cell Renal Cell Carcinoma (ccRCC): The K-COMPASS Model
- Biomarker assay development, validation & clinical testing solutions tailored for drug programmes
- Flexible platforms, chemistries & technologies for multiple diseases indications
- Support for global regulatory strategies including EU (IVDR) and FDA
- Pharma Case Study: Learn how Almac has supported Global clinical studies